Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche To File NDA For T-DM1 This Year

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche confirms mid-single digit sales growth for 2010 in first-quarter earnings call, as oncology and emerging markets sales provide a boost.

You may also be interested in...



ImmunoGen Gains Momentum On Success Of T-DM1, The Herceptin Conjugate In Development By Roche/Genentech

Buoyed by the affirmation of its conjugation technology brought by the imminent filing of T-DM1, ImmunoGen is focused on building an internal pipeline with future emphasis co-development deals, not just outlicensing.

ImmunoGen Gains Momentum On Success Of T-DM1, The Herceptin Conjugate In Development By Roche/Genentech

Buoyed by the affirmation of its conjugation technology brought by the imminent filing of T-DM1, ImmunoGen is focused on building an internal pipeline with future emphasis co-development deals, not just outlicensing.

Making Expanded Access Programs Work For - Not Against - Your Trial Drug

Providing an investigational drug outside of a controlled trial carries inherent development risks, but it can also be a win-win proposition for patients and sponsors when managed well, veterans of "expanded access" programs say

Related Content

Topics

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel